-Dr. Robin Edwards and Dr. David Ferry join Dragonfly’s clinical leadership team to help manage its growing clinical portfolio
Six drugs developed by Dragonfly are currently in the clinic.
WALTHAM, Mass., June 1, 2023 /PRNewswire/ — Dragonfly Therapeutics, Inc., today announced that it has expanded its clinical leadership team with the addition of Dr. Robin Edwards, previously Global Director of Translational Sciences at Daiichi Sankyo and Translational Director at Bristol Myers Squibb, and Dr. David Ferry, formerly Director of GI Oncology at Eli Lilly.
“The encouraging clinical results we are seeing with our three proprietary drug programs, and our plan to rapidly expand our clinical footprint in the coming years, are leading us to double the size of our clinical team by 2023,” said Bill Haney. , CEO and co-founder of Dragonfly. “Robin and David, who will lead Translational Medicine and Oncology Clinical Development, respectively, are fantastic additions to the Dragonfly team.”
Earlier this year, Dr. Joe Eid, who led the pioneering clinical development of KEYTRUDA® at Merck and was also previously Head of Global Medical Affairs at BMS, joined Dragonfly as President of Research and Development.
Dragonfly’s growing portfolio of clinical products includes a Phase 1/2 study of DF1001, a HER2-targeted immunomodulator TriNKET®, a Phase 1 study of its novel cytokine interleukin-12 (IL12) DF6002, a Phase 1 study of its DF9001 TriNKET targeting EGFR for solid tumor cancers; and a fourth proprietary cytokine program scheduled for IND submission later this year. Including the assets in association, Dragonfly currently has a total of six drugs in clinical study around the world.
“We are delighted that Robin and David have joined Dragonfly,” said Dr. Joe. Eid, Dragonfly’s president of Research and Development. “His impressive achievements and deep experience in drug development will be invaluable as we manage our novel drug candidates in the clinic, supporting our partner programs with existing collaborators BMS, Merck, AbbVie and Gilead – which currently include three programs TriNKETs developed by Dragonfly that are in the clinic – and expanding our portfolio of wholly owned clinical assets.”
About Dragonfly Dragonfly Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapies that use its novel technology to harness the body’s immune system and deliver innovative treatments to patients. Dragonfly has a broad pipeline of proprietary preclinical and clinical candidates, discovered through its proprietary platform, advancing to the clinical phase, as well as productive collaborations with Bristol Myers Squibb, Merck, and AbbVie across a wide range of diseases. For more information, visit us at www.Dragonflytx.com, or follow us on Linkedin and Twitter.
DRAGONFLY MEDIA CONTACT: Anne E. Deconinck | anne@dragonflytx.com
Logo – https://mma.prnewswire.com/media/390962/…
View original content: https://www.prnewswire.com/news-releases/dr-robin-edwards-y-dr-david-ferry-se-unen-al-equipo-de-liderazgo-clinico-de-dragonfly-301840550.html
